BRAMPTON, ON, Oct. 20, 2016 /CNW/ - Medtronic Canada, a
subsidiary of Medtronic plc (NYSE:MDT), announced today the Health
Canada licence of its MiniMed™ 630G system with SmartGuard™
technology for people with diabetes mellitus. The MiniMed 630G
system features a new insulin pump hardware platform and a new
user-friendly design that combines personalized diabetes management
with industry-leading clinical performance. The MiniMed 630G system
is the newest offering of the MiniMed family-the #1 selling pump
brand in Canada†.
After interviewing more than 1,000 people with diabetes and
testing user-experience, the enhanced features of the MiniMed 630G
system were finalized to take into account what matters most to
those with diabetes. This collaborative process with the patient
community resulted in a new, user-friendly pump design that is
waterproof1 and features a high-definition, full-colour
screen that supports easy navigation and enables increased
customization with more intuitive menus.
"We are excited to announce the launch of the MiniMed 630G
system for Canadians living with diabetes. This latest
innovation is a step towards Medtronic's vision of transforming
diabetes care and our commitment to providing improved outcomes and
an improved user experience for our customers," said Laura Cameron, Director of Diabetes &
Consumer Care in Canada.
The MiniMed 630G system combines its proprietary SmartGuard
technology with a brand new user-friendly design. The new pump
platform fully integrates continuous glucose monitoring (CGM) and
SmartGuard technology, which is designed to trigger an alarm when
the CGM sensor glucose level reaches a preset low limit and
suspends insulin delivery if the user is unresponsive to the alarm.
SmartGuard technology is the only feature available in Canada that takes action against
lows2 and is the only system proven to reduce the
frequency of nighttime low episodes3 by a
third.2,4
Data from the ASPIRE In-Home Study published in the New England
Journal of Medicine2 demonstrated that SmartGuard
technology not only reduces the number of low events2
per week by 30 percent but also shortens the length/intensity of
those events at night by 37.5 % without increasing A1C (a measure
of average blood sugar levels over three months).4 These
results were validated with real-world data from the company's
CareLink™ Personal software that included an analysis of 581,822
days of data in Canada, which
demonstrated SmartGuard technology users experience about half as
many nighttime lows3 than those using a pump and sensor
alone.5 MiniMed integrated insulin pump technology with
CGM has also been proven to provide better glucose control than
multiple daily injections without increasing hypoglycemia (low
blood sugar).6
The MiniMed 630G system with SmartGuard technology will be
commercially available in Canada
in early 2017.
About the Diabetes Group at Medtronic
(www.medtronicdiabetes.ca)
Medtronic is working together with the global community to change
the way people manage diabetes. The company aims to help transform
diabetes care by expanding access, integrating care and improving
outcomes, so people living with diabetes can enjoy greater freedom
and better health.
About Medtronic
Medtronic Canada (www.medtronic.ca),
headquartered in Brampton, Ontario
is a subsidiary of Medtronic plc, which is among the world's
largest medical technology, services and solutions companies —
alleviating pain, restoring health and extending life for millions
of people around the world. Medtronic is proud to employ over 1,600
people in Canada, serving
physicians, hospitals and patients across the country. The company
is focused on collaborating with stakeholders around the world to
take healthcare Further, Together.
Any forward-looking statements are subject to risks and
uncertainties such as those described in Medtronic's periodic
reports on file with the Securities and Exchange Commission. Actual
results may differ materially from anticipated
results.
_______________
1 MiniMed 630G is waterproof in up to 3.6 meters (12
feet) of water for up to 24 hours at the time of manufacture;
Guardian Link Transmitter is waterproof in up to 2.4 meters (8
feet) of water for up to 30 minutes. See IFU for additional
information on the waterproof feature.
2 Bergenstal RM, Klonoff DC, Garg SK, et al.
Threshold-based insulin-pump interruption for reduction of
hypoglycemia. N Engl J Med. 2013;369(3):224-232.
3 Measured in sensor glucose values.
4 Based upon limited sample size and duration of ASPIRE
In-Home study.
5 Data from only the voluntary CareLink® Personal
Uploads from the Veo system OUS available from May 1, 2011 to October 20,
2015 evaluated.
6 Bergenstal RM, Tamborlane WV, Ahmann A, et al.
Effectiveness of sensor-augmented insulin-pump therapy in type 1
diabetes. N Engl J Med 2010;363:311-320.
†Based on sales. Data on file.
SOURCE Medtronic Canada